Biocytogen partner NEOK Bio gets FDA nod for novel cancer therapy
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
Subscribe To Our Newsletter & Stay Updated